Loading...
XSTO
SPAGO
Market cap4mUSD
Jul 09, Last price  
0.12SEK
1D
-3.36%
1Q
-3.77%
Jan 2017
-99.14%
IPO
-99.02%
Name

Spago Nanomedical AB (publ)

Chart & Performance

D1W1MN
XSTO:SPAGO chart
P/E
—
P/S
88.74
EPS
—
Div Yield, %
—
Shrs. gr., 5y
45.24%
Rev. gr., 5y
5.02%
Revenues
437k
-77.13%
981,000222,000228,00054,0007,515,00058,00047,00029,644,00030,000342,000660,0001,054,0001,203,0001,911,000437,000
Net income
-27m
L-18.32%
-715,000-4,615,000-5,214,000-6,131,000-6,791,000-7,540,000-9,457,000-11,092,000-20,280,000-18,903,000-39,075,000-39,309,000-42,223,000-32,509,000-26,554,000
CFO
-28m
L-18.38%
-276,000-601,000-7,737,000-5,952,000-5,345,000-7,863,000-7,730,000-10,510,000-21,288,000-18,766,000-35,569,000-38,187,000-44,909,000-34,668,000-28,297,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Operating primarily in Sweden, Spago Nanomedical AB (publ) is dedicated to pioneering nanomedicines for both the diagnosis and treatment of cancer. The company is actively pursuing two key projects: the SpagoPix initiative, centered on SN132D, a gadolinium-free MRI contrast agent developed for imaging breast and pancreatic cancers; and the Tumorad project, which is advancing SN201, a radionuclide therapy intended for managing advanced and metastatic forms of cancer. Originally established as Spago Imaging AB (publ), the company adopted its current name, Spago Nanomedical AB (publ), in May 2014. Founded in 1999, its base of operations is situated in Lund, Sweden.
URL
https://spagonanomedical.se/
IPO date
Jan 15, 2013
Employees
13
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT